 Hepatic sensitivity effects sulfonylurea drugs Insulin regulation hepatic glucose production HGP non-insulin-dependent diabetes NIDDM glucose output liver elevation plasma glucose concentration basal state restoration normal insulin action liver goal hypoglycemic therapy Sulfonylureas treatment NIDDM past years addition stimulatory effect insulin secretion compounds extrapancreatic effects Early vitro studies addition sulfonylureas perfusion medium liver preparations significant suppressive effect HGP Subsequent experience compounds level insulin receptor various postreceptor sites studies sulfonylureas glycogenolysis gluconeogenesis glycogen synthesis Results vivo NIDDM patients agreement vitro studies Long-term treatment sulfonylureas decline plasma glucose concentration parallel reduction HGP Nevertheless direct effect sulfonylurea administration liver unclear reduction HGP sulfonylurea treatment secondary overall improvement insulin secretion interest insulin-dependent diabetic patients sulfonylurea administration combination insulin injections significant change HGP Possible effects sulfonylureas glucagon secretion metabolism free fatty acids FFAs improved sensitivity liver suppressive action insulin agents plasma glucagon FFA concentrations present data support extrapancreatic action sulfonylureas liver certain degree residual insulin secretion sulfonylurea agents hepatic effect